TY - JOUR
T1 - Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy
AU - Oh, Jae K.
AU - Velazquez, Eric J.
AU - Menicanti, Lorenzo
AU - Pohost, Gerald M.
AU - Bonow, Robert O.
AU - Lin, Grace
AU - Hellkamp, Anne S.
AU - Ferrazzi, Paolo
AU - Wos, Stanislaw
AU - Rao, Vivek
AU - Berman, Daniel
AU - Bochenek, Andrzej
AU - Cherniavsky, Alexander
AU - Rogowski, Jan
AU - Rouleau, Jean L.
AU - Lee, Kerry L.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Aims The Surgical Treatment for Ischemic Heart Failure (STICH) trial demonstrated no overall benefit when surgical ventricular reconstruction (SVR) was added to coronary artery bypass grafting (CABG) in patients with ischaemic cardiomyopathy. The present analysis was to determine whether, based on baseline left ventricular (LV) function parameters, any subgroups could be identified that benefited from SVR.Methods and resultsAmong the 1000 patients enrolled, Core Lab measures of baseline LV function with adequate quality were obtained in 710 patients using echocardiography, in 352 using cardiovascular magnetic resonance, and in 344 using radionuclide imaging. The relationship between LV end-systolic volume index (ESVI), end-diastolic volume index, ejection fraction (EF), regional wall motion abnormalities, and outcome were first assessed only by echocardiographic measures, and then by 13 algorithms using a different hierarchy of imaging modalities and their quality. The median ESVI and EF were 78.0 (range: 22.8-283.8) mL/m2 and 28.0%, respectively. Hazard ratios comparing the randomized arms by subgroups of LVESVI and LVEF measured by echocardiography found that patients with smaller ventricles (LVESVI 2) and better LVEF (≥33%) may have benefitted by SVR, while those with larger ventricles (LVESVI >90 mL/m2) and lower LVEF (≤25%) did worse with SVR. Algorithms using all three imaging modalities found a weaker relationship between LV global function and the effects of SVR. The extent of regional wall motion abnormality did not influence the effects of SVR. Conclusion sSubgroup analyses of the STICH trial suggest that patients with less dilated LV and better LVEF may benefit from SVR, while those with larger LV and poorer LVEF may do worse.Clinical Trial Registration #: NCT00023595.
AB - Aims The Surgical Treatment for Ischemic Heart Failure (STICH) trial demonstrated no overall benefit when surgical ventricular reconstruction (SVR) was added to coronary artery bypass grafting (CABG) in patients with ischaemic cardiomyopathy. The present analysis was to determine whether, based on baseline left ventricular (LV) function parameters, any subgroups could be identified that benefited from SVR.Methods and resultsAmong the 1000 patients enrolled, Core Lab measures of baseline LV function with adequate quality were obtained in 710 patients using echocardiography, in 352 using cardiovascular magnetic resonance, and in 344 using radionuclide imaging. The relationship between LV end-systolic volume index (ESVI), end-diastolic volume index, ejection fraction (EF), regional wall motion abnormalities, and outcome were first assessed only by echocardiographic measures, and then by 13 algorithms using a different hierarchy of imaging modalities and their quality. The median ESVI and EF were 78.0 (range: 22.8-283.8) mL/m2 and 28.0%, respectively. Hazard ratios comparing the randomized arms by subgroups of LVESVI and LVEF measured by echocardiography found that patients with smaller ventricles (LVESVI 2) and better LVEF (≥33%) may have benefitted by SVR, while those with larger ventricles (LVESVI >90 mL/m2) and lower LVEF (≤25%) did worse with SVR. Algorithms using all three imaging modalities found a weaker relationship between LV global function and the effects of SVR. The extent of regional wall motion abnormality did not influence the effects of SVR. Conclusion sSubgroup analyses of the STICH trial suggest that patients with less dilated LV and better LVEF may benefit from SVR, while those with larger LV and poorer LVEF may do worse.Clinical Trial Registration #: NCT00023595.
KW - Coronary disease
KW - Heart failure
KW - STICH
KW - Surgical ventricular reconstruction
UR - http://www.scopus.com/inward/record.url?scp=84871989851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871989851&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehs021
DO - 10.1093/eurheartj/ehs021
M3 - Article
C2 - 22584648
AN - SCOPUS:84871989851
VL - 34
SP - 39
EP - 47
JO - European Heart Journal
JF - European Heart Journal
SN - 0195-668X
IS - 1
ER -